After years of research and development of numerous candidate compounds, the FDA approval of the PDE4 inhibitors roflumilast and apremilast in 2011 and 2014 for the treatment of COPD and psoriatic arthritis represent important breakthroughs for the use of PDE inhibitors in the therapy of human inflammatory disorders. This evidence concerns the gene PDE4A and psoriatic arthritis.